Publications 2014
193.
Filip S1, Zoidakis J, Vlahou A, Mischak H.
Advances in urinary proteome analysis and applications in systems biology.
Bioanalysis. 2014 Oct;6(19):2549-69. doi: 10.4155/bio.14.210.
192.
Silva S, Bronze M R, Figueira M, Siwy J, Mischak H, Combet E, Mullen W
Impact of a 6-wk olive oil supplementation in healthy adults on urinary proteomic biomarkers of coronary artery disease, chronic kidney disease, and diabetes (types 1 and 2): a randomized, parallel, controlled, double-blind study
AJCN. First published ahead of print November 19, 2014 as doi: 10.3945/ajcn.114.094219.
191.
Bhat A, Dakna M, Mischak H.
Integrating proteomics profiling data sets: a network perspective.
Methods Mol Biol. 2015;1243:237-53. doi: 10.1007/978-1-4939-1872-0_14.
190.
Stalmach A, Husi H, Mosbahi K, Albalat A, Mullen W, Mischak H.
Methods in capillary electrophoresis coupled to mass spectrometry for the identification of clinical proteomic/peptidomic biomarkers in biofluids.
Methods Mol Biol. 2015;1243:187-205. doi: 10.1007/978-1-4939-1872-0_11.
189.
Seetho IW, Siwy J, Albalat A, Mullen W, Mischak H, Parker RJ, Craig S, Duffy N, Hardy KJ, Burniston JG, Wilding JP.
Urinary proteomics in obstructive sleep apnoea and obesity.
Eur J Clin Invest. 2014 Nov;44(11):1104-15. doi: 10.1111/eci.12346.
188.
Nkuipou-Kenfack E, Koeck T, Mischak H, Pich A, Schanstra JP, Zürbig P, Schumacher B.
Proteome analysis in the assessment of ageing.
Ageing Res Rev. 2014 Sep 22;18C:74-85. doi: 10.1016/j.arr.2014.09.002. [Epub ahead of print] Review.
187.
Stalmach A, Johnsson H, McInnes IB, Husi H, Klein J, Dakna M, Mullen W, Mischak H, Porter D.
Identification of urinary Peptide biomarkers associated with rheumatoid arthritis.
PLoS One. 2014 Aug 21;9(8):e104625. doi: 10.1371/journal.pone.0104625. eCollection 2014.
186.
Zhang Z, Staessen JA, Thijs L, Gu Y, Liu Y, Jacobs L, Koeck T, Zürbig P, Mischak H, Kuznetsova T.
Left ventricular diastolic function in relation to the urinary proteome: A proof-of-concept study in a general population.
Int J Cardiol. 2014 Jul 12. pii: S0167-5273(14)01206-6. doi: 10.1016/j.ijcard.2014.07.014. [Epub ahead of print]
185.
Gu YM, Thijs L, Liu YP, Zhang Z, Jacobs L, Koeck T, Zürbig P, Lichtinghagen R, Brand K, Kuznetsova T, Olivi L, Verhamme P, Delles C, Mischak H, Staessen JA.
The urinary proteome as correlate and predictor of renal function in a population study.
Nephrol Dial Transplant. 2014 Jun 30. pii: gfu234. [Epub ahead of print]
184.
Filip S, Pontillo C, Peter Schanstra J, Vlahou A, Mischak H, Klein J.
Urinary proteomics and molecular determinants of chronic kidney disease: possible link to proteases.
Expert Rev Proteomics. 2014 Jun 24:1-14. [Epub ahead of print]
183.
Koss MJ, Hoffmann J, Nguyen N, Pfister M, Mischak H, Mullen W, Husi H, Rejdak R, Koch F, Jankowski J, Krueger K, Bertelmann T, Klein J, Schanstra JP, Siwy J.
Proteomics of vitreous humor of patients with exudative age-related macular degeneration.
PLoS One. 2014 May 14;9(5):e96895. doi: 10.1371/journal.pone.0096895. eCollection 2014.
182.
Nkuipou-Kenfack E, Duranton F, Gayrard N, Argilés A, Lundin U, Weinberger KM, Dakna M, Delles C, Mullen W, Husi H, Klein J, Koeck T, Zürbig P, Mischak H.
Assessment of metabolomic and proteomic biomarkers in detection and prognosis of progression of renal function in chronic kidney disease.
PLoS One. 2014 May 9;9(5):e96955. doi: 10.1371/journal.pone.0096955. eCollection 2014.
181.
Mullen W, Saigusa D, Abe T, Adamski J, Mischak H.
Proteomics and Metabolomics as Tools to Unravel Novel Culprits and Mechanisms of Uremic Toxicity: Instrument or Hype?
Semin Nephrol. 2014 Mar;34(2):180-190. doi: 10.1016/j.semnephrol.2014.02.009. Epub 2014 Feb 18. Review.
180.
Schanstra JP, Mischak H.
Proteomic urinary biomarker approach in renal disease: from discovery to implementation.
Pediatr Nephrol. 2014 Mar 15. [Epub ahead of print]
179.
Siwy J, Schanstra JP, Argiles A, Bakker SJ, Beige J, Boucek P, Brand K, Delles C, Duranton F, Fernandez-Fernandez B, Jankowski ML, Al Khatib M, Kunt T, Lajer M, Lichtinghagen R, Lindhardt M, Maahs DM, Mischak H, Mullen W, Navis G, Noutsou M, Ortiz A, Persson F, Petrie JR, Roob JM, Rossing P, Ruggenenti P, Rychlik I, Serra AL, Snell-Bergeon J, Spasovski G, Stojceva-Taneva O, Trillini M, von der Leyen H, Winklhofer-Roob BM, Zürbig P, Jankowski J.
Multicentre prospective validation of a urinary peptidome-based classifier for the diagnosis of type 2 diabetic nephropathy.
Nephrol Dial Transplant. 2014 Mar 2. [Epub ahead of print]
178.
Husi H, Van Agtmael T, Mullen W, Bahlmann FH, Schanstra JP, Vlahou A, Delles C, Perco P, Mischak H.
Proteome-Based Systems Biology Analysis of the Diabetic Mouse Aorta Reveals Major Changes in Fatty Acid Biosynthesis as Potential Hallmark in Diabetes Associated Vascular Disease.
Circ Cardiovasc Genet. 2014 Feb 26. [Epub ahead of print]
177.
Mischak H1, Vlahou A2, Righetti PG3, Calvete JJ4.
Putting value in biomarker research and reporting.
J Proteomics. 2014 Jan 16;96:A1-3. doi: 10.1016/j.jprot.2013.12.002.
176.
Albalat A, Husi H, Stalmach A, Schanstra JP, Mischak H.
Classical MALDI-MS versus CE-based ESI-MS proteomic profiling in urine for clinical applications.
Bioanalysis. 2014 Jan;6(2):247-66. doi: 10.4155/bio.13.313.
175.
Klein J, Buffin-Meyer B, Mullen W, Carty DM, Delles C, Vlahou A, Mischak H, Decramer S, Bascands JL, Schanstra JP.
Clinical proteomics in obstetrics and neonatology.
Expert Rev Proteomics. 2014 Jan 3. [Epub ahead of print]
174.
Frantzi M, Metzger J, Banks RE, Husi H, Klein J, Dakna M, Mullen W, Cartledge JJ, Schanstra JP, Brand K, Kuczyk MA, Mischak H, Vlahou A, Theodorescu D, Merseburger AS.
Discovery and Validation of Urinary Biomarkers for Detection of Renal Cell Carcinoma.
J Proteomics. 2013 Dec 24. pii: S1874-3919(13)00645-3. doi: 10.1016/j.jprot.2013.12.010. [Epub ahead of print]
173.
Klein J, Papadopoulos T, Mischak H, Mullen W.
Comparison of CE-MS/MS and LC-MS/MS sequencing demonstrates significant complementarity in natural peptide identification in human urine.
Electrophoresis. 2013 Oct 8. doi: 10.1002/elps.201300327. [Epub ahead of print]
172.
Duranton F, Lundin U, Gayrard N, Mischak H, Aparicio M, Mourad G, Daurès JP, Weinberger KM, Argilés A.
Plasma and Urinary Amino Acid Metabolomic Profiling in Patients with Different Levels of Kidney Function.
Clin J Am Soc Nephrol. 2013 Nov 14. [Epub ahead of print]
171.
Mermelekas G, Makridakis M, Koeck T, Vlahou A.
Redox proteomics: from residue modifications to putative biomarker identification by gel- and LC-MS-based approaches.
PMID: 24206227 [PubMed - in process]
170.
Husi H, Sanchez-Niño MD, Delles C, Mullen W, Vlahou A, Ortiz A, Mischak H.
A combinatorial approach of Proteomics and Systems Biology in unravelling the mechanisms of acute kidney injury (AKI): involvement of NMDA receptor GRIN1 in murine AKI.
BMC Syst Biol. 2013 Oct 30;7(1):110. [Epub ahead of print]
169.
Dissard R, Klein J, Caubet C, Breuil B, Siwy J, Hoffman J, Sicard L, Ducassé L, Rascalou S, Payre B, Buléon M, Mullen W, Mischak H, Tack I, Bascands JL, Buffin-Meyer B, Schanstra JP.
Long Term Metabolic Syndrome Induced by a High Fat High Fructose Diet Leads to Minimal Renal Injury in C57BL/6 Mice.
PLoS One. 2013 Oct 3;8(10):e76703.
168.
Neuhaus J, Schiffer E, Siwy J, Mannello F, Horn LC, Stolzenburg JU
Proteome-based diagnostic and prognostic biomarkers of prostate cancer.
Urologe A. 2013 Sep;52(9):1251-5. doi: 10.1007/s00120-013-3308-0.
167.
Latosinska A, Frantzi M, Vlahou A, Mischak H
Clinical applications of capillary electrophoresis coupled to mass spectrometry in biomarker discovery: Focus on Bladder Cancer.
Proteomics Clin Appl. 2013 Aug 23. doi: 10.1002/prca.201300038. [Epub ahead of print]
166.
Klein J, Lacroix C, Caubet C, Siwy J, Zürbig P, Dakna M, Muller F, Breuil B, Stalmach A, Mullen W, Mischak H, Bandin F, Monsarrat B, Bascands JL, Decramer S, Schanstra JP.
Fetal Urinary Peptides to Predict Postnatal Outcome of Renal Disease in Fetuses with Posterior Urethral Valves (PUV).
Sci Transl Med. 2013 Aug 14;5(198):198ra106. doi: 10.1126/scitranslmed.3005807.
165.
Albalat A, Stalmach A, Bitsika V, Siwy J, Schanstra JP, Petropoulos AD, Vlahou A, Jankowski J, Persson F, Rossing P, Jaskolla TW, Mischak H, Husi H.
Improving peptide relative quantification in MALDI-TOF MS for biomarker assessment.
Proteomics. 2013 Oct;13(20):2967-75. doi: 10.1002/pmic.201300100.
164.
Frantzi M, Zoidakis J, Papadopoulos T, Zurbig P, Katafigiotis I, Stravodimos K, Lazaris A, Giannopoulou I, Ploumidis A, Mischak H, Mullen WB, Vlahou A.
IMAC fractionation in combination to LC/MS reveals H2B and NIF-1 peptides as potential bladder cancer biomarkers.
J Proteome Res. 2013 Aug 7. [Epub ahead of print]
163.
Weissinger EM, Metzger J, Dobbelstein C, Wolff D, Schleuning M, Kuzmina Z, Greinix H, Dickinson AM, Mullen W, Kreipe H, Hamwi I, Morgan M, Krons A, Tchebotarenko I, Ihlenburg-Schwarz D, Dammann E, Collin M, Ehrlich S, Diedrich H, Stadler M, Eder M, Holler E, Mischak H, Krauter J, Ganser A.
Proteomic peptide profiling for preemptive diagnosis of acute graft-versus-host-disease after allogeneic stem cell transplantation.
Leukemia. 2013 Jul 11. doi: 10.1038/leu.2013.210. [Epub ahead of print]
162.
Suárez ER, Siwy J, Zürbig P, Mischak H.
Urine as a source for clinical proteome analysis: From discovery to clinical application.
Biochim Biophys Acta. 2013 Jul 2. pii: S1570-9639(13)00253-7. doi: 10.1016/j.bbapap.2013.06.016. [Epub ahead of print]
161.
Neuhaus J, Schiffer E, Wilcke P, Bauer HW, Leung H, Siwy J, Ulrici W, Paasch U, Horn LC, Stolzenburg J
Seminal Plasma as a Source of Prostate Cancer Peptide Biomarker Candidates for Detection of Indolent and Advanced Disease
PLoS ONE 8(6): e67514. doi:10.1371/journal.pone.0067514
160.
Klein G, Schanstra JP, Hoffmann J, Mischak H, Siwy J
Proteomics as a Quality Control Tool of Pharmaceutical Probiotic Bacterial Lysate Products
PLoS ONE 8(6): e66682. doi:10.1371/journal.pone.0066682
159.
Argilés A, Siwy J, Duranton F, Gayrard N, Dakna M, Lundin U, Osaba L, Delles C, Mourad G, Weinberger KM, Mischak H.
CKD273, a New Proteomics Classifier Assessing CKD and Its Prognosis.
PLoS One. 2013 May 14;8(5):e62837. doi: 10.1371/journal.pone.0062837. Print 2013.
158.
Jankowski V, Schulz A, Kretschmer A, Mischak H, Boehringer F, van der Giet M, Janke D, Schuchardt M, Herwig R, Zidek W, Jankowski J.
The enzymatic activity of the VEGFR2 receptor for the biosynthesis of dinucleoside polyphosphates.
J Mol Med (Berl). 2013 May 1. [Epub ahead of print]
157.
Mansor R, Mullen W, Albalat A, Zerefos P, Mischak H, Barrett DC, Biggs A, Eckersall PD
A peptidomic approach to biomarker discovery for bovine mastitis.
J Proteomics. 2013 Jun 24;85:89-98. doi: 10.1016/j.jprot.2013.04.027. Epub 2013 Apr 30.
156.
Stalmach A, Albalat A, Mullen W, Mischak H.
Recent advances in capillary electrophoresis coupled to mass spectrometry for clinical proteomic applications.
Electrophoresis. 2013 Jun;34(11):1452-64. doi: 10.1002/elps.201200708. Epub 2013 May 8.
155.
Klein J, Eales J, Zürbig P, Vlahou A, Mischak H, Stevens R.
Proteasix: a tool for automated and large-scale prediction of proteases involved in naturally-occurring peptide generation.
Proteomics. 2013 Apr;13(7):1077-82. doi: 10.1002/pmic.201200493. Epub 2013 Feb 26.
154.
Kistler AD, Serra AL, Siwy J, Poster D, Krauer F, Torres VE, Mrug M, Grantham JJ, Bae KT, Bost JE, Mullen W, Wüthrich RP, Mischak H, Chapman AB.
Urinary proteomic biomarkers for diagnosis and risk stratification of autosomal dominant polycystic kidney disease: a multicentric study.
PLoS One. 2013;8(1):e53016. doi: 10.1371/journal.pone.0053016. Epub 2013 Jan 10.
153.
Siwy J, Zoja C, Klein J, Benigni A, Mullen W, Mayer B, Mischak H, Jankowski J, Stevens R, Vlahou A, Kossida S, Perco P, Bahlmann FH.
Evaluation of the Zucker Diabetic Fatty (ZDF) Rat as a Model for Human Disease Based on Urinary Peptidomic Profiles.
PLoS One. 2012;7(12):e51334. doi: 10.1371/journal.pone.0051334. Epub 2012 Dec 7.
152.
Zürbig P, Jahn H.
Use of proteomic methods in the analysis of human body fluids in Alzheimer research.
Electrophoresis. 2012 Dec;33(24):3617-30. doi: 10.1002/elps.201200360.
151.
Roscioni SS, de Zeeuw D, Hellemons ME, Mischak H, Zürbig P, Bakker SJ, Gansevoort RT, Reinhard H, Persson F, Lajer M, Rossing P, Heerspink HJ.
A urinary peptide biomarker set predicts worsening of albuminuria in type 2 diabetes mellitus.
Diabetologia. 2013 Feb;56(2):259-67. doi: 10.1007/s00125-012-2755-2. Epub 2012 Oct 20.
150.
Mischak H, Vlahou A, Ioannidis JP.
Technical aspects and inter-laboratory variability in native peptide profiling: The CE-MS experience.
Clin Biochem. 2013 Apr;46(6):432-43.
149.
Albalat A, Franke J, Gonzalez J, Mischak H, Zürbig P.
Urinary proteomics based on capillary electrophoresis coupled to mass spectrometry in kidney disease.
Methods Mol Biol. 2013;919:203-13.
148.
Herget-Rosenthal S, Metzger J, Albalat A, Bitsika V, Mischak H.
Proteomic biomarkers for the early detection of acute kidney injury.
Prilozi. 2012 Jul;33(1):27-48.
147.
Duranton F, Cohen G, De Smet R, Rodriguez M, Jankowski J, Vanholder R, Argiles A; European Uremic Toxin Work Group.
Normal and pathologic concentrations of uremic toxins.
J Am Soc Nephrol. 2012 Jul;23(7):1258-70. Epub 2012 May 24.
146.
Carty DM, Schiffer E, Delles C.
Proteomics in hypertension
J Hum Hypertens. 2013 Apr;27(4):211-6. doi: 10.1038/jhh.2012.30. Epub 2012 Aug 9
145.
Zürbig P, Jerums G, Hovind P, MacIsaac R, Mischak H, Nielsen SE, Panagiotopoulos S, Persson F, Rossing P.
Urinary Proteomics for Early Diagnosis in Diabetic Nephropathy.
Diabetes. 2012 Dec;61(12):3304-13. doi: 10.2337/db12-0348. Epub 2012 Aug 7.
144.
Molin L, Seraglia R, Lapolla A, Ragazzi E, Gonzalez J, Vlahou A, Schanstra JP, Albalat A, Dakna M, Siwy J, Jankowski J, Bitsika V, Mischak H, Zürbig P, Traldi P.
A comparison between MALDI-MS and CE-MS data for biomarker assessment in chronic kidney diseases.
J Proteomics. 2012 Oct 22;75(18):5888-97. doi: 10.1016/j.jprot.2012.07.024. Epub 2012 Jul 26.
143.
Mischak H
How to get proteomics to the clinic? Issues in clinical proteomics, exemplified by CE-MS.
Proteomics Clin Appl. 2012 Oct;6(9-10):437-42. doi: 10.1002/prca.201200027. Epub 2012 Sep 24.
142.
Kuznetsova T, Mischak H, Mullen W, Staessen JA
Urinary proteome analysis in hypertensive patients with left ventricular diastolic dysfunction.
Eur Heart J. 2012 Sep;33(18):2342-50. Epub 2012 Jul 11.
141.
Dawson J, Walters M, Delles C, Mischak H, Mullen W.
Urinary proteomics to support diagnosis of stroke.
PLoS One. 2012;7(5):e35879. Epub 2012 May 16.
140.
Metzger J, Negm AA, Plentz RR, Weismüller TJ, Wedemeyer J, Karlsen TH, Dakna M, Mullen W, Mischak H, Manns MP, Lankisch TO
Urine proteomic analysis differentiates cholangiocarcinoma from primary sclerosing cholangitis and other benign biliary disorders
Gut. 2013 Jan;62(1):122-30. doi: 10.1136/gutjnl-2012-302047. Epub 2012 May 12.
139.
Mischak H, Ioannidis JP, Argiles A, Attwood TK, Bongcam-Rudloff E, Broenstrup M, Charonis A, Chrousos GP, Delles C, Dominiczak A, Dylag T, Ehrich J, Egido J, Findeisen P, Jankowski J, Johnson RW, Julien BA, Lankisch T, Leung HY, Maahs D, Magni F, Manns MP, Manolis E, Mayer G, Navis G, Novak J, Ortiz A, Persson F, Peter K, Riese HH, Rossing P, Sattar N, Spasovski G, Thongboonkerd V, Vanholder R, Schanstra JP, Vlahou A.
Implementation of proteomic biomarkers: making it work.
Eur J Clin Invest. 2012 Sep;42(9):1027-1036. doi: 10.1111/j.1365-2362.2012.02674.x. Epub 2012 Apr 21.
138.
Mullen W, Albalat A, Gonzalez J, Zerefos P, Siwy J, Franke J, Mischak H.
Performance of different separation methods interfaced in the same MS-reflection TOF detector: A comparison of performance between CE versus HPLC for biomarker analysis.
Electrophoresis. 2012 Feb;33(4):567-74. doi: 10.1002/elps.201100415.
137.
Rouse R, Siwy J, Mullen W, Mischak H, Metzger J, Hanig J
Proteomic Candidate Biomarkers of Drug-Induced Nephrotoxicity in the Rat
PLoS ONE. 2012;7(4): e34606
136.
von zur Muhlen C, Schiffer E, Sackmann C, Zürbig P, Neudorfer I, Zirlik A, Htun N, Iphöfer A, Jänsch L, Mischak H, Bode C, Chen YC, Peter K
Urine proteome analysis reflects atherosclerotic disease in an ApoE-/- mouse model and allows the discovery of new biomarkers in mouse and human atherosclerosis
Mol Cell Proteomics. 2012 Jul;11(7):M111.013847. Epub 2012 Feb 27.
135.
Bandin F, Siwy J, Breuil B, Mischak H, Bascands JL, Decramer S, Schanstra JP
Urinary Proteome Analysis at 5-Year Followup of Patients With Nonoperated Ureteropelvic Junction Obstruction Suggests Ongoing Kidney Remodeling.
J Urol. 2012 Mar;187(3):1006-11. Epub 2012 Jan 20.
134.
Mullen W, Gonzalez J, Siwy J, Franke J, Sattar N, Mullan A, Roberts S, Delles C, Mischak H, Albalat A.
A Pilot Study on the Effect of Short-Term Consumption of a Polyphenol Rich Drink on Biomarkers of Coronary Artery Disease Defined by Urinary Proteomics.
J Agric Food Chem. 2011 Dec 28;59(24):12850-7.
133.
Schiffer E, Bick C, Grizelj B, Pietzker S, Schöfer W
Urinary proteome analysis for prostate cancer diagnosis: Cost-effective application in routine clinical practice in Germany
Int J Urol. 2012 Feb;19(2):118-25. doi: 10.1111/j.1442-2042.2011.02901.x. Epub 2011 Nov 22.
132.
Jahn H, Wittke S, Zürbig P, Raedler TJ, Arlt S, Kellmann M, Mullen W, Eichenlaub M, Mischak H, Wiedemann K
Peptide fingerprinting of Alzheimer´s disease in cerebrospinal fluid: Identification and prospective evaluation of new synaptic biomarkers
PLoS ONE 2011 Oct; 6(10): e26540
131.
Drube J, Schiffer E, Lau E, Petersen C, Kirschstein M, Kemper M, Lichtinghagen R, Ure B, Mischak H, Pape L, Ehrich JH
Urinary Proteome Analysis to Exclude Severe Vesicoureteral Reflux
Pediatrics. 2012 Feb;129(2):e356-63. Epub 2012 Jan 23.
130.
Albalat A, Mischak H, Mullen W.
Clinical application of urinary proteomics/peptidomics.
Expert Rev Proteomics. 2011 Oct;8(5):615-29.
129.
Mullen W, Delles C, Mischak H; members of EuroKUP COST action.
Urinary proteomics in the assessment of chronic kidney disease.
Curr Opin Nephrol Hypertens. 2011 Nov;20(6):654-61.
128.
Mischak H, Thongboonkerd V, Schanstra JP, Vlahou A
Renal and urinary proteomics.
Proteomics Clin Appl. 2011 Jun;5(5-6):211-3. doi: 10.1002/prca.201190031.
127.
Albalat A, Mischak H, Mullen W
Urine proteomics in clinical applications: technologies, principal considerations and clinical implementation.
Prilozi. 2011 Jul;32(1):13-44.
126.
Kistler AD, Siwy J, Breunig F, Jeevaratnam P, Scherl A, Mullen W, Warnock DG, Wanner C, Hughes DA, Mischak H, Wüthrich RP, Serra AL
A distinct urinary biomarker pattern characteristic of female Fabry patients that mirrors response to Enzyme Replacement Therapy
PLoS One. 2011;6(6):e20534. Epub 2011 Jun 15.
125.
Zürbig P, Dihazi H, Metzger J, Thongboonkerd V, Vlahou A
Urine proteomics in kidney and urogenital diseases: Moving towards clinical applications.
Proteomics Clin Appl. 2011 Jun;5(5-6):256-68. doi: 10.1002/prca.201000133.
124.
Siwy J, Mullen W, Golovko I, Franke J, Zürbig P
Human urinary peptide database for multiple disease biomarker discovery.
Proteomics Clin Appl. 2011 Jun;5(5-6):367-74. doi: 10.1002/prca.201000155.
123.
Metzger J, Chatzikyrkou C, Broecker V, Schiffer E, Jaensch L, Iphoefer A, Mengel M, Mullen W, Mischak H, Haller H, Gwinner W
Diagnosis of subclinical and clinical acute T-cell-mediated rejection in renal transplant patients by urinary proteome analysis
Proteomics Clin Appl. 2011 Jun;5(5-6):322-33. doi: 10.1002/prca.201000153.
122.
Schiffer E, Liabeuf S, Lacroix C, Temmar M, Renard C, Monsarrat B, Choukroun G, Lemke HD, Vanholder R, Mischak H, Massy ZA; on behalf of the European Uremic Toxin Work Group (EUTox).
Markers of vascular disease in plasma from patients with chronic kidney disease identified by proteomic analysis.
J Hypertens. 2011 Apr;29(4):783-790.
121.
Carty DM, Siwy J, Brennand JE, Zürbig P, Mullen W, Franke J, McCulloch JW, North RA, Chappell LC, Mischak H, Poston L, Dominiczak AF, Delles C.
Urinary Proteomics for Prediction of Preeclampsia.
Hypertension. 2011 Mar;57(3):561-9.
120.
Ehrich JH, Schiffer E, Drube J.
Urinary proteomics : The diagnostic key for urinary tract abnormalities and kidney diseases in children?
Urologe A. 2011 Feb;50(2):170-179.
119.
Mayer G, Heinze G, Mischak H, Hellemons ME, Heerspink HJ, Bakker SJ, de Zeeuw D, Haiduk M, Rossing P, Oberbauer R
Omics-bioinformatics in the context of clinical data.
Methods Mol Biol. 2011;719:479-97.
118.
Mischak H, Schanstra JP.
CE-MS in biomarker discovery, validation, and clinical application.
Proteomics Clin Appl. 2011 Feb;5(1-2):9-23. doi: 10.1002/prca.201000058. 11.
117.
Schiffer E
Urinary proteomics: ready for prime time in urological cancer diagnostics?
Personalized Medicine 2011, Jan;8 (1): 81-94.
116.
Siwy J, Vlahou A, Zimmerli LU, Zürbig P, Schiffer E
Clinical proteomics: Current techniques and potential applications in the elderly
Maturitas. 2011 Mar;68(3):233-44
115.
Foucher C, Schiffer E, Mischak H, Ansquer JC, Wilbraham D
Effect of fenofibrate treatment on the low molecular weight urinary proteome of healthy volunteers
Proteomics Clin Appl. 2011 Apr;5(3-4):159-66. doi: 10.1002/prca.201000076
114.
Lankisch TO, Metzger J, Negm AA, Voßkuhl K, Schiffer E, Siwy J, Weismüller TJ, Andrea S. Schneider AS, Thedieck K, Baumeister R, Zuerbig P, Weissinger EM, Manns MP, Mischak H, Wedemeyer J
Bile proteomic profiles differentiates cholangiocarcinoma from primary sclerosing cholangitis and choledocholithiasis
Hepatology. 2011 Mar;53(3):875-884. doi: 10.1002/hep.24103
113.
Dakna M, Keith H, Kalousis A, Carpentier S, Kolch W, Schanstra JP, Haubitz M, Vlahou A, Mischak H, Girolami M.
Addressing the Challenge of Defining Valid Proteomic Biomarkers and Classifiers.
BMC Bioinformatics. 2010 Dec 10;11:594
112.
Mischak H, Delles C, Klein J, Schanstra JP
Urinary proteomics based on capillary electrophoresis coupled mass spectrometry in kidney disease: discovery and validation of biomarkers, and clinical application.
Advances in Chronic Kidney Disease 2010 Nov; Vol 17, No 6: pp 493-506
View Abstract Request Reprint
111.
Andersen S, Mischak H, Zuerbig P, Parving HH, Rossing P
Urinary proteome analysis enables assessment of renoprotective treatment in type 2 diabetic patients with microalbuminuria
BMC Nephrol. 2010 Nov 1;11:29. doi: 10.1186/1471-2369-11-29.
110.
Alkhalaf A, Zuerbig P, Bakker SJL, Bilo HJG, Cerna M, Fischer C, Fuchs S, Janssen B, Medek K, Mischak H, Roob JM, Rossing K, Rossing P, Rychlík I, Sourij H, Tiran B, Winklhofer-Roob BM, Navis GJ
Multicentric Validation of Proteomic Biomarkers in Urine Specific for Diabetic Nephropathy
PLoS ONE 2010 Oct; 5(10): e13421
109.
Maahs DM, Siwy J, Argilés À, Cerna M, Delles C, Dominiczak AF, Gayrard N, Iphöfer A, Jänsch L, Jerums G, Medek K, Mischak H, Navis G, Roob JM, Rossing K, Rossing P, Rychlík I, Schiffer E, Schmieder RE, Wascher TC, Winklhofer-Roob BM, Zimmerli LU, Zürbig P, Snell-Bergeon JK
Urinary Collagen Fragments are Significantly Altered in Diabetes: a Link to Pathophysiology
PLoS ONE 2010 Sep; 5(9). pii: e13051
108.
Metzger J, Kirsch T, Schiffer E, Ulger P, Mentes E, Brand K, Weissinger EM, Haubitz M, Mischak H, Herget-Rosenthal S
Diagnostic marker pattern of sequenced urinary peptides for early and accurate detection of acute kidney injury
Kidney International 2010
107.
Zürbig P, Mischak H
Proteomanalyse in der Diagnostik von Nierenerkrankungen
MedReview, 2010
106.
Mischak H, Rossing P.
Proteomic biomarkers in diabetic nephropathy - reality or future promise?
Nephrol Dial Transplant. 2010 Jun 22
105.
Mischak H, Kolch W, Aivaliotis M, Bouyssie D, Court M, Dihazi H, Dihazi GH, Franke J, Garin J, de Peredo AG, Iphoefer A, Jänsch L, Lacroix C, Makridakis M, Masselon C, Metzger J, Monsarrat B, Mrug M, Norling M, Novak J, Pich A, Pitt A, Bongcam-Rudloff E, Siwy J, Suzuki H, Thongboonkerd V, Wang L, Zoidakis J, Zuerbig P, Schanstra J, Vlahou A
Comprehensive human urine standards for comparability and standardization in clinical proteome analysis.
Proteomics Clinical Applications 2010; 4:464-478
104.
Griner EM, Caino MC, Sosa MS, Colon-Gonzalez F, Chalmers MJ, Mischak H, Kazanietz MG
A novel cross-talk in diacylglycerol signaling: the Rac-GAP {beta}2-chimaerin is negatively regulated by PKC{delta} mediated phosphorylation.
J Biol Chem. 2010 May 28;285(22):16931-41
103.
Good DM, Zürbig P, Argilés A, Bauer HW, Behrens G, Coon JJ, Dakna M, Decramer S, Delles C, Dominiczak AF, Ehrich JHH, Eitner F, Fliser D, Frommberger M, Ganser A, Girolami MA, Golovko I, Gwinner W, Haubitz M, Herget-Rosenthal S, Jankowski J, Jahn H, Jerums G, Julian BA, Kellmann M, Kliem V, Kolch W, Krolewski AS, Luppi M, Massy Z, Melter M, Neusüss C, Novak J, Peter K, Rossing K, Rupprecht H , Schanstra JP, Schiffer E, Stolzenburg JU, Tarnow L, Theodorescu D, Thongboonkerd V, Vanholder R, Weissinger EM, Mischak H, Schmitt-Kopplin P
Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease.
Mol Cell Proteomics. 2010 Nov;9(11):2424-37.
102.
Delles C, Schiffer E, von zur Muhlen C, Peter K, Rossing P, Parving HH, Dymott JA a, Neisius U, Zimmerli LUa, Snell-Bergeon JK, Maahs DM, Schmieder RE, Mischak H, Dominiczak AF
Urinary proteomic diagnosis of coronary artery disease: identification and clinical validation in 623 subjects
J Hypertens. 2010 Nov;28(11):2316-22.
101.
Mischak H, Allmaier G, Apweiler R, Attwood T, Baumann M, Benigni A, Bennett SE, Bischoff R, Bongcam-Rudloff E, Capasso G, Coon JJ, D’Haese P, Dominiczak AF, Dakna M, Dihazi H, Ehrich JH, Fernandez-Llama P, Fliser D, Frokiaer J, Garin J, Girolami M, Hancock WS, Haubitz M, Hochstrasser D, Holman R, Ioannidis JPA, Jankowski J, Julian BA, Klein JB, Kolch W, Luider T, Massy Z, Mattes WB, Molina F, Monsarrat B, Novak J, Peter K, Rossing P, Sánchez-Carbayo M, Schanstra JP, Semmes OJ, Spasovsk G, Theodorescu D, Thongboonkerd V, Vanholder R, Veenstra T, Weissinger E, Yamamoto T, Vlahou A
Recommendations for biomarker identification and qualification in clinical proteomics.
Science Translational Medicine Papers 2010
100.
Drube J, Zürbig P, Schiffer E, Lau E, Ure B, Glüer S, Kirschstein M, Pape L, Decramer S, Bascands JL, Schanstra JP, Mischak H, Ehrich JH.
Urinary proteome analysis identifies infants but not older children requiring pyeloplasty.
Pediatr Nephrol. 2010 Sep;25(9):1673-8
99.
Caubet C, Lacroix C, Decramer S, Drube J, Ehrich JHH, Mischak H, Bascands JL, Schanstra JP
Advances in urinary proteome analysis and biomarker discovery in pediatric renal disease.
Pediatr Nephrol. 2010 Jan;25(1):27-35
98.
Schiffer E.
The 2nd annual oncology biomarkers conference.
Biomark Med. 2009 Apr;3(2):203-9.
97.
Vanholder R, Abou-Deif O, Argiles A, Baurmeister U, Beige J, Brouckaert P, Brunet P, Cohen G, De Deyn PP, Drueke TB, Fliser D, Glorieux G, Herget-Rosenthal S, Horl WH, Jankowski J, Jorres A, Massy ZA, Mischak H, Perna AF, Rodriguez-Portillo JM, Spasovski G, Stegmayr BG, Stenvinkel P, Thornalley PJ, Wanner C, Wiecek A
The role of EUTox in uremic toxin research.
Seminars in dialysis 2009 Jul-Aug; 22 (4): 323-328.
96.
Vlahou A, Allmaier G, Attwood T, Bongcam-Rudloff E, Charonis A, Frokiaer J, Mischak H, Schanstra J, Spasovski G.
2nd Combined Working Group and Management Committee Meeting of Urine and Kidney Proteomics COST Action 29-30 March 2009, Nafplio, Greece.
Proteomics Clin Appl. 2009 Sep;3(9):1017-22.
95.
Zürbig P, Mischak H, Conrads S
Urinary proteome analysis for early diagnosis of diabetes and its complications /
Eiweißanalyse im Urin zur frühen Diagnose des Diabetes und seiner Komplikationen
Diabetes, Stoffwechsel und Herz, Heft 6, 2009 Jahrgang 18
94.
Weissinger EM, Zürbig P, Ganser A.
Proteomics studies after hematopoietic stem cell transplantation.
Methods Mol Biol. 2009;506:437-52
View Abstract Request Reprint
93.
Zürbig P, Schiffer E, Mischak H.
Capillary electrophoresis coupled to mass spectrometry for proteomic profiling of human urine and biomarker discovery
Methods Mol Biol. 2009;564:105-21
92.
Schiffer E, Vlahou A, Petrolekas A, Stravodimos K, Tauber R, Geschwend JE, Neuhaus J, Stolzenburg JU, Conaway MR, Mischak H, Theodorescu D
Prediction of Muscle-invasive Bladder Cancer Using Urinary Proteomics
Clin Cancer Res. 2009 Aug 1;15(15):4935-43
View Publisher Website Request Reprint
91.
Dhillona AS, Yipa YY, Grindlay GJ, Pakaya JL, Dangers M, Hillmann M, Clark W, Pitte A, Mischak H, Kolch W
The C-terminus of RAF-1 acts as a 14-3-3-dependent activation switch
Cell Signal. 2009 Nov;21(11):1645-51
View Publisher Website Request Reprint
90.
Jankowski V, Giet M, Mischak H, Morgan M, Zidekm W, Jankowski J
Dinucleoside polyphosphates: strong endogenous agonists of the purinergic system (review)
Br J Pharmacol 2009 Aug;157(7):1142-53
View Publisher Website Request Reprint
89.
Haubitz M, Good DM, Woywodt A, Haller H, Rupprecht H, Theodorescu D, Dakna M, Coon J, Mischak H
Identification and Validation of Urinary Biomarkers for Differential Diagnosis and Evaluation of Therapeutic Intervention in ANCA associated Vasculitis
Mol Cell Proteomics. 2009 Oct;8(10):2296-307
View Publisher Website Request Reprint
88.
Mischak H, Espandiari P, Sadrieh N, Hanig J
Profiling of rat urinary proteomic patterns associated with drug-induced nephrotoxicity using capillary electrophoresis coupled with mass spectrometry as a potential model for detection of drug-induced adverse effects
PROTEOMICS - Clinical Applications 2009
View Publisher Website Request Reprint
87.
Kistler A, Mischak H, Poster D, Dakna M, Wuthrich R, Serra A
Identification of a unique urinary biomarker profile in autosomal dominant polycystic kidney disease
Kidney Int. 2009 Jul;76(1):89-96
View Publisher Website Request Reprint
86.
Weissinger EM, Mischak H, Kontsendorn J, Hahn A, Hahn N, Morgan M, Ganser A
Proteome analysis in hematology using capillary electrophoresis coupled on-line to mass spectrometry
Mini Rev Med Chem. 2009 May;9(5):627-3
View Publisher Website Request Reprint
85.
Metzger J, Luppa PB, Good DM, Mischak H
Adapting mass spectrometry-based platforms for clinical proteomics applications: the capillary electrophoresis coupled mass spectrometry paradigm
Crit Rev Clin Lab Sci. 2009;46(3):129-52
View Publisher Website Request Reprint
84.
Drube J, Schiffer E, Mischak H, Kemper M, Neuhaus T, Pape L, Lichtinghagen R, Ehrich JHH
Urinary proteome pattern in children with renal Fanconi syndrome
Nephrol Dial Transplant. 2009 Jul;24(7):2161-9. Epub 2009 Feb 18
83.
Dakna M, He Z, Yu WC, Mischak H, Kolch W
Technical, bioinformatical and statistical aspects of liquid chromatography-mass spectrometry (LC-MS) and capillary electrophoresis-mass spectrometry (CE-MS) based clinical proteomics: a critical assessment
Journal of Chromatography B 2009, 877(13): 1250-1258
82.
Mischak H, Massy ZA, Jankowski J
Proteomics and uremia and renal disease
Seminars in Dialysis 2009
81.
Zürbig P, Decramer S, Dakna M, Jantos J, Good DM, Coon JJ, Bandin F, Mischak H, Bascands JL, Schanstra JP.
The human urinary proteome reveals high similarity between kidney aging and chronic kidney disease.
Proteomics. 2009 Apr;9(8):2108-17
80.
Schiffer E, Mischak H, Zimmerli LU
Proteomics in gerontology - current applications and future aspects
Gerontology. 2009;55(2):123-37. Epub 2009 Jan 9
79.
Muhlen C, Schiffer E, Zuerbig P, Kellmann M, Brasse M, Meert N, Vanholder RC, Dominiczak AF, Chen YC, Mischak H, Bode C, Peter K
Evaluation of Urine Proteome Pattern Analysis for Its Potential To Reflect Coronary Artery Atherosclerosis in Symptomatic Patients
Journal of Proteome Research 2009, 8(1): 335-345
78.
Snell-Bergeon JK, Maahs DM, Ogden LG, Kinney GL, Hokanson JE, Schiffer E, Mischak H, Rewers M
Evaluation of urinary biomarkers for coronary artery disease, diabetes, and diabetic kidney disease
Diabetes, Technology and Therapeutics 2009, 11(1): 1-9
77.
Mischak H, Coon JJ, Novak J, Weissinger EM, Schanstra J, Dominiczak AF
Capillary electrophoresis–mass spectrometry as a powerful tool in biomarker discovery and clinical diagnosis: an update of recent developments
Mass Spectrom Rev. 2009 Sep-Oct;28(5):703-24
76.
Jantos-Siwy J, Schiffer E, Brand K, Schumann G, Rossing K, Delles C, Mischak H, Metzger J
Quantitative urinary proteome analysis for biomarker evaluation in chronic kidney disease
Journal of Proteome Research 2009, 8(1): 268-281
75.
Metzger J, Schanstra JP, Mischak H
Capillary electrophoresis-mass spectrometry in urinary proteome analysis: current applications and future developments
Anal Bioanal Chem. 2009 Mar;393(5):1431-42. Epub 2008 Aug 15
74.
Haubitz M, Mischak H, Julian BA, Novak J
Urinary Protein Patterns as a Diagnostic Tool for Patients with Immunoglobulin A Nephropathy
European Renal Disease - Touch Briefings 2007
73.
Vlahou A, Schanstra J, Frokiaer J, El Nahas M, Spasovski G, Mischak H, Domon B, Allmaier G, Bongcam-Rudloff E, Attwood T; On behalf of the European Kidney and Urine Proteomics Network
Establishment of a European Network for Urine and Kidney Proteomics
J Proteomics 2008, 71(4): 490-492
72.
Decramer S, Gonzalez de Peredo A, Breuil B, Mischak H, Monsarrat B, Bascands JL, Schanstra JP
Urine in clinical proteomics
Mol Cell Proteomics 2008, 7(10): 1850-1862
71.
Jiang H, Schiffer E, Song Z, Wang J, Zurbig P, Thedieck K, Moes S, Bantel H, Saal N, Jantos J, Brecht M, Jenoe P, Hall MN, Hager K, Manns MP, Hecker H, Ganser A, Doehner K, Bartke A, Meissner C, Mischak H, Ju Z, Rudolph KL
Proteins induced by telomere dysfunction and DNA damage represent biomarkers of human aging and disease
Proc Natl Acad Sci (USA) 2008, 105(32): 11299-11304
70.
Vanholder R, Baurmeister U, Brunet P, Cohen G, Glorieux G, Jankowski J
A bench to bedside view of uremic toxins
J Am Soc Nephrol. 2008, 19: 863-870
69.
Coon JJ, Zurbig P, Dakna M, Dominiczak AF, Decramer S, Fliser D, Frommberger M, Golovko I, Good DM, Herget-Rosenthal S, Jankowski J, Julian BA, Kellmann M, Kolch W, Massy Z, Novak J, Rossing K, Schanstra JP, Schiffer E, Theodorescu D, Vanholder R, Weissinger EM, Mischak H, Schmitt-Kopplin P
CE-MS analysis of the human urinary proteome for biomarker discovery and disease diagnostics
PROTEOMICS - Clinical Applications 2008, 2(7-8): 964-973
68.
Schiffer E, Mischak H, Vanholder RC
Exploring the uremic toxins using proteomic technologies
Contrib Nephrol. 2008, 160: 159-171
67.
Decramer S, Zurbig P, Wittke S, Mischak H, Bascands JL, Schanstra JP
Identification of urinary biomarkers by proteomics in newborns: use in obstructive nephropathy
Contrib Nephrol. 2008, 160: 127-141
66.
Zurbig P, Mischak H
Capillary electrophoresis coupled to mass spectrometry for biomarker discovery and diagnosis of kidney diseases
Contrib Nephrol. 2008, 160: 107-126
65.
Rossing K, Mischak H, Rossing P, Schanstra JP, Wiseman A, Maahs DM
The urinary proteome in diabetes and diabetes-associated complications: new ways to assess disease progression and evaluate therapy
PROTEOMICS - Clinical Applications 2008, 2(7-8): 997-1007
64.
Raedler T, Wittke S, Jahn H, Kössler A, Mischak H, Wiedemann K
Capillary electrophoresis mass spectrometry as a potential tool to detect lithium-induced nephropathy: Preliminary results
Prog Neuropsychopharmacol Biol Psychiatry 2008, 32(3): 673-678
63.
Rossing K, Mischak H, Dakna M, Zürbig P, Novak J, Julian BA, Good DM, Coon JJ, Tarnow L, Rossing P
Proteomic Discovery and Evaluation of Urinary Biomarkers for Diabetes and Chronic Renal Disease
J Am Soc Nephrol. 2008, 19(7): 1283-1290
62.
Schiffer E, Mischak H, Theodorescu, Vlahou A
Challenges of using mass spectrometry as a bladder cancer biomarker discovery platform
World Journal of Urology 2008, 26(1): 67-74
61.
Theodorescu D, Schiffer E, Bauer HW, Douwes F, Eichhorn F, Polley R, Schmidt T, Schöfer W, Zurbig P, Good DM, Coon JJ, Mischak H
Discovery and validation of urinary biomarkers for prostate cancer
PROTEOMICS - Clinical Applications 2008, 2(4): 556-570
60.
Mathivanan S, et al., Mischak H, et al., Zurbig P, Pandey A
Human Proteinpedia: A portal for sharing and integration of human protein data
Nature Biotechnology 2008, 26(2): 164-167
59.
Zimmerli LU, Schiffer E, Zurbig P, Good DM, Kellmann M, Mouls L, Pitt AR, Coon JJ, Schmieder RE, Peter K, Mischak H, Kolch W, Delles C, Dominiczak AF
Urinary proteomic biomarkers in coronary artery disease
Mol Cell Proteomics 2008, 7(2): 290-298
58.
Goodsaid F, Bandow JE, Mischak H
REPORT - Grand Rounds in Proteomics at the FDA (White Oak, Silver Spring, MD, USA, April 3, 2007)
PROTEOMICS - Clinical Applications 2007, 1: 1526-1531
57.
Good DM, Thongboonkerd V, Novak J, Bascands JL, Schanstra JP, Coon JJ, Dominiczak A, Mischak H
Body Fluid Proteomics for Biomarker Discovery: Lessons from the Past Hold the Key to Success in the Future
J Proteome Res. 2007, 6(12): 4549-4555
56.
Julian BA, Wittke S, Novak J, Good D, Coon JJ, Kellmann M, Zurbig P, Schiffer E, Haubitz M, Moldoveanu Z, Calcatera S, Wyatt R, Sykora J, Sladkova E, Hes O, Mischak H, Mc Guire B
Electrophoretic methods for analysis of urinary polypeptides in IgA-associated renal diseases
Electrophoresis 2007, 28(23): 4469-4483
55.
Schiffer E
Biomarkers for prostate cancer
World Journal of Urology 2007, 25(6): 557-562
54.
Vanholder R, Meert N, Schepers E, Glorieux G, Argiles A, Brunet P, Cohen G, Drueke T, Mischak H, Spasovski G, Massy Z, Jankowski J; for the European Uremic Toxin Work Group (EUTox)
Review on uraemic solutes II Variability in reported concentrations: causes and consequences
Nephrol Dial Transplant. 2007, 22(11): 3115-3121
53.
Geppert HG, Mischak H
Klinische Proteomanalyse zur effektiven Gesundheitsvorsorge
journal of preventive medicine 2007, 3(3+4): 330-337
52.
Geppert HG
Polypeptide zeigen pathologische Prozesse
Nachrichten aus der Chemie 2007, 55: 1020-1021
51.
Julian BA, Wittke S, Haubitz M, Zurbig P, Schiffer E, McGuire BM, Wyatt RJ, Novak J
Urinary biomarkers of IgA nephropathy and other IgA-associated renal diseases
World Journal of Urology 2007, 35(5): 467-476
50.
Decramer S, Bascands JL, Schanstra JP
Non-invasive markers of ureteropelvic junction obstruction
World Journal of Urology 2007, 25(5): 457-465
49.
Theodorescu D, Mischak H
Mass spectrometry based proteomics in urine biomarker discovery
World J Urol. 2007, 25(5): 435-443
48.
Geppert HG, von zur Mühlen C, Mischak H
Proteomanalyse zur Erkennung und Therapieevaluierung der koronaren Herzkrankheit
journal of preventive medicine 2007, 3(2): 160-168
47.
Wittke S, Schiffer E, Bauer HW
Kapillarelektrophorese gekoppelte Massenspektrometrie zur Proteomanalyse: Eine innovative diagnostische Methode bei Prostata- und Blasenkrebs
Der Urologe 2007, 46(7): 733-739
46.
Weissinger EM, Schiffer E, Hertenstein B, Ferrara JL, Holler E, Stadler M, Kolb HJ, Zander A, Zurbig P, Kellmann M, Ganser A
Proteomic patterns predict acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation
Blood 2007, 109(12): 5511-5519
45.
Sniehotta M, Schiffer E, Zurbig P, Novak J, Mischak H
CE - a multifunctional application for clinical diagnosis
Electrophoresis 2007, 28(9): 1407-1417
44.
Fliser D, Novak J, Thongboonkerd V, Argiles A, Jankowski V, Girolami MA, Jankowski J, Mischak H
Advances in urinary proteome analysis and biomarker discovery
J Am Soc Nephrol. 2007, 18(4): 1057-1071
43.
Mischak H, Pantke U, Fliser D
Proteomanalyse zur Erkennung, Früherkennung und Therapieevaluierung der diabetischen Nephropathie
journal of preventive medicine 2007, 3(1): 28-35
42.
Ehrich J, Mischak A, Mischak H
Proteomanalyse
Österreichische Ärztezeitung 2007, 6: 49-53
41.
Frommberger M, Zurbig P, Jantos J, Krahn T, Mischak H, Pich A, Just I, Schmitt-Kopplin P, Schiffer E
Peptidomic analysis of rat urine using capillary electrophoresis coupled to mass spectrometry
PROTEOMICS - Clinical Applications 2007, 1: 650-660
40.
Mischak H, Julian BA, Novak A
High-resolution proteome/peptidome analysis of peptides and low-molecular-weight proteins in urine
PROTEOMICS - Clinical Applications 2007, 1: 792-804
39.
Mischak H, Apweiler R, Banks RE, Conaway M, Coon J, Dominiczak A, Ehrich JHH, Fliser D, Girolami M, Hermjakob H, Hochstrasser D, Jankowski J, Julian BA, Kolch W, Massy ZA, Neusuess C, Novak J, Peter K, Rossing K, Schanstra J, Semmes OJ, Theodorescu D, Thongboonkerd V, Weissinger EM, van Eyk JE, Yamamoto T
Clinical Proteomics: a need to define the field and to begin to set adequate standards
PROTEOMICS - Clinical Applications 2007, 1: 148-156
38.
Weissinger EM, Mischak H
Application of proteomics to posttransplantational follow-up
Methods Mol Med. 2007, 134: 217-228
37.
Schiffer E, Mischak H, Novak J
High resolution proteome/peptidome analysis of body fluids by capillary electrophoresis coupled with MS
Proteomics 2006, 6(20): 5615-5627
36.
Mischak H
Hochauflösende Proteomanalyse aus Urin in der nicht invasiven Diagnostik von Tumoren und chronischen Erkrankungen
prevention and anti aging 2006, 2(4): 426-435
35.
Zurbig P, Renfrow MB, Schiffer E, Novak J, Walden M, Wittke S, Just I, Pelzing M, Neususs C, Theodorescu D, Root KE, Ross MM, Mischak H
Biomarker discovery by CE-MS enables sequence analysis via MS/MS with platform-independent separation
Electrophoresis 2006, 27(11): 2111-2125
34.
Gwinner W, Rohde F, Mischak H
Proteome analysis as a noninvasive tool in transplant monitoring
Biomarkers 2006, May: May
33.
Decramer S, Wittke S, Mischak H, Zurbig P, Walden M, Bouissou F, Bascands JL, Schanstra JP
Predicting the clinical outcome of congenital unilateral ureteropelvic junction obstruction in newborn by urinary proteome analysis
Nat Med. 2006, 12(4): 398-400
32.
Weissinger EM, Mischak H, Ganser A, Hertenstein B
Value of proteomics applied to the follow-up in stem cell transplantation
Ann Hematol. 2006, 85(4): 205-211
31.
Theodorescu D, Wittke S, Ross MM, Walden M, Conaway M, Just I, Mischak H, Frierson HF
Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis
Lancet Oncol. 2006, 7(3): 230-240
30.
Weissinger EM, Nguyen-Khoa T, Saltiel C, Buisson C, Walden M, Kaiser T, Mischak H, Drüeke TB, Lacour B, Massy ZA
Effects of oral vitamin C supplementation on oxidative stress and inflammation status in hemodialysis patients – Classical and proteomic assessment
Proteomics 2006, 6(3): 993-1000
29.
Thongboonkerd V, Cutillas PR, Unwin RJ, Schaub S, Nickerson P, Haubitz M, Mischak H, Nedelkov D, Kiernan U, Nelson RW
Proteomics of Human Urine
Thongboonkerd V (Ed.) 2006, Proteomics of Human Body Fluids: Principles, Methods, and Applications
28.
Walden M, Wittke S, Mischak H, Vanholder RC
Proteomics of human dialysate and ultrafiltrate fluids yielded by renal replacement therapy
Thongboonkerd V (Ed.) 2006, Proteomics of Human Body Fluids: Principles, Methods, and Applications
27.
Girolami M, Mischak H, Krebs R
Analysis of complex, multidimensional datasets
Drug Dicovery Today: Analytical technologies 2006, 3(1): 13-19
26.
Kolch W, Neususs C, Pelzing M, Mischak H
Capillary electrophoresis-mass spectrometry as a powerful tool in clinical diagnosis and biomarker discovery
Mass Spectrom Rev. 2005, 24(6): 959-977
25.
Chalmers MJ, Mackay CL, Hendrickson CL, Wittke S, Walden M, Mischak H, Fliser D, Just I, Marshall AG
Combined top-down and bottom-up mass spectrometric approach to characterization of biomarkers for renal disease
Anal Chem. 2005, 77(22): 7163-7171
24.
Weissinger EM, Hertenstein B, Mischak H, Ganser A
Online coupling of capillary electrophoresis with mass spectrometry for the identification of biomarkers for clinical diagnosis
Expert Reviews In: Proteomics 2005, 2(5): 639-647
23.
Wittke S, Haubitz M, Walden M, Rohde F, Schwarz A, Mengel M, Mischak H, Haller H, Gwinner W
Detection of acute tubulointerstitial rejection by proteomic analysis of urinary samples in renal transplant recipients
Am J Transplant. 2005, 5(10): 2479-2488
22.
Meier M, Kaiser T, Herrmann A, Knueppel S, Hillmann M, Koester P, Danne T, Haller H, Fliser D, Mischak H
Identification of urinary protein pattern in type 1 diabetic adolescents with early diabetic nephropathy by a novel combined proteome analysis
J Diabetes Complications. 2005, 19(4): 223-232
21.
Rossing K, Mischak H, Parving HH, Christensen PK, Walden M, Hillmann M, Kaiser T
Impact of diabetic nephropathy and angiotensin II receptor blockade on urinary polypeptide patterns
Kidney Int. 2005, 68(1): 193-205
20.
Theodorescu D, Fliser D, Wittke S, Mischak H, Krebs R, Walden M, Ross M, Eltze E, Bettendorf O, Wulfing C, Semjonow A
Pilot study of capillary electrophoresis coupled to mass spectrometry as a tool to define potential prostate cancer biomarkers in urine
Electrophoresis. 2005, 26(14): 2797-2808
19.
Fliser D, Wittke S, Mischak H
Capillary electrophoresis coupled to mass spectrometry for clinical diagnostic purposes
Electrophoresis. 2005, 26(14): 2708-2716
18.
Haubitz M, Wittke S, Weissinger EM, Walden M, Rupprecht HD, Floege J, Haller H, Mischak H
Urine protein patterns can serve as diagnostic tools in patients with IgA nephropathy
Kidney Int. 2005, 67(6): 2313-2320
17.
Kolch W, Mischak H, Pitt AR
The molecular make-up of a tumour: proteomics in cancer research
Clin Sci (Lond). 2005, 108(5): 369-383
16.
Wittke S, Mischak H, Walden M, Kolch W, Radler T, Wiedemann K
Discovery of biomarkers in human urine and cerebrospinal fluid by capillary electrophoresis coupled to mass spectrometry: towards new diagnostic and therapeutic approaches
Electrophoresis. 2005, 26(7-8): 1476-1487
15.
Hillman M, Mischak H
CE-MS as a Tool for Renal Disease Analysis and Biomarker Discovery Pace Setter
The worldwide newsletter for capillary electrophoresis (Beckman Coulter) 2005, 9(2): 1-5
14.
Walden M, Mischak H
Proteomanalyse mittels Kapillarelektrophorese-gekoppelter Massenspektrometrie - ein neues Routineverfahren in der klinischen Diagnostik?
Klinische Chemie Mitteilungen 2005, 36(5): 87-101
13.
Weissinger EM, Kaiser T, Meert N, De Smet R, Walden M, Mischak H, Vanholder RC
Proteomics: a novel tool to unravel the patho-physiology of uraemia
Nephrol Dial Transplant. 2004, 19(12): 3068-3077
12.
Mischak H, Kaiser T, Walden M, Hillmann M, Wittke S, Herrmann A, Knueppel S, Haller H, Fliser D
Proteomic analysis for the assessment of diabetic renal damage in humans
Clin Sci (Lond). 2004, 107(5): 485-495
11.
Kolch W, Mischak H, Chalmers MJ, Pitt A, Marshall AG
Clinical proteomics: a question of technology
Rapid Commun Mass Spectrom. 2004, 18(19): 2365-2366
10.
Kaiser T, Wittke S, Just I, Krebs R, Bartel S, Fliser D, Mischak H, Weissinger EM
Capillary electrophoresis coupled to mass spectrometer for automated and robust polypeptide determination in body fluids for clinical use
Electrophoresis 2004, 25(13): 2044-2055
9.
Kaiser T, Kamal H, Rank A, Kolb HJ, Holler E, Ganser A, Hertenstein B, Mischak H, Weissinger EM
Proteomics applied to the clinical follow-up of patients after allogeneic hematopoietic stem cell transplantation
Blood 2004, 104(2): 340-349
8.
Weissinger EM, Wittke S, Kaiser T, Haller H, Bartel S, Krebs R, Golovko I, Rupprecht HD, Haubitz M, Hecker H, Mischak H, Fliser D
Proteomic patterns established with capillary electrophoresis and mass spectrometry for diagnostic purposes
Kidney Int. 2004, 65(6): 2426-2434
7.
Haubitz M, Fliser D, Haller H
Proteomanalyse – eine neue Perspektive für die klinische Diagnostik
Deutsches Ärzteblatt 2004, 101(21): A-1514 / B-1255 / C-1207
6.
Wittke S, Kaiser T, Mischak H
Differential polypeptide display: the search for the elusive target
J Chromatogr B Analyt Technol Biomed Life Sci. 2004, 803(1): 17-26
5.
Chalmers MJ, Kolch W, Emmett MR, Marshall AG, Mischak H
Identification and analysis of phosphopeptides
J Chromatogr B Analyt Technol Biomed Life Sci. 2004, 803(1): 111-120
4.
Neuhoff N, Kaiser T, Wittke S, Krebs R, Pitt A, Burchard A, Sundmacher A, Schlegelberger B, Kolch W, Mischak H
Mass spectrometry for the detection of differentially expressed proteins: a comparison of surface-enhanced laser desorption/ionization and capillary electrophoresis/mass spectrometry
Rapid Commun Mass Spectrom. 2004, 18(2): 149-156
3.
Weissinger EM, Mischak H
Proteom analysis applied towards early diagnosis of renal diseases and transplant-monitoring
Transplantationsmedizin 2004, 16: 2-9
2.
Kaiser T, Hermann A, Kielstein JT, Wittke S, Bartel S, Krebs R, Hausadel F, Hillmann M, Golovko I, Koester P, Haller H, Weissinger EM, Fliser D, Mischak H
Capillary electrophoresis coupled to mass spectrometry to establish polypeptide patterns in dialysis fluids
J Chromatogr A. 2003, 1013(1-2): 157-171
1.
Wittke S, Fliser D, Haubitz M, Bartel S, Krebs R, Hausadel F, Hillmann M, Golovko I, Koester P, Haller H, Kaiser T, Mischak H, Weissinger EM
Determination of peptides and proteins in human urine with capillary electrophoresis-mass spectrometry, a suitable tool for the establishment of new diagnostic markers
J Chromatogr A. 2003, 1013(1-2): 173-181